Do analysts recommend TAK or INSM?

Insmed has a consensus target price of $210.95, suggesting a potential upside of 103.37%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Insmed 1 Sell rating(s) 0 Hold rating(s) 23 Buy rating(s) 1 Strong Buy rating(s) 2.96

Does the media refer more to TAK or INSM?

In the previous week, Insmed had 15 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 17 mentions for Insmed and 2 mentions for Takeda Pharmaceutical. Insmed's average media sentiment score of 1.50 beat Takeda Pharmaceutical's score of 1.09 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, ARGX or INSM?

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 11.74 $1.29B $22.46 35.72 Insmed $606.42M 37.08 -$1.28B -$5.75 N/A

Is ARGX or INSM more profitable?

argenex has a net margin of 31.31% compared to Insmed's net margin of -144.44%. argenex's return on equity of 33.28% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 33.28% 28.16% Insmed -144.44% -130.11% -51.57%

Does the media refer more to ARGX or INSM?

In the previous week, Insmed had 10 more articles in the media than argenex. MarketBeat recorded 17 mentions for Insmed and 7 mentions for argenex. Insmed's average media sentiment score of 1.50 beat argenex's score of 0.58 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to TEVA or INSM?

In the previous week, Teva Pharmaceutical Industries had 1 more articles in the media than Insmed. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 17 mentions for Insmed. Insmed's average media sentiment score of 1.50 beat Teva Pharmaceutical Industries' score of 1.37 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 13 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, ONC or INSM?

BeOne Medicines has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BeOne Medicines $5.34B 5.64 $286.93M $4.47 61.45 Insmed $606.42M 37.08 -$1.28B -$5.75 N/A

Is ONC or INSM more profitable?

BeOne Medicines has a net margin of 8.94% compared to Insmed's net margin of -144.44%. BeOne Medicines' return on equity of 12.06% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets BeOne Medicines 8.94% 12.06% 6.69% Insmed -144.44% -130.11% -51.57%

Does the media refer more to ONC or INSM?

In the previous week, Insmed had 5 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Insmed and 12 mentions for BeOne Medicines. Insmed's average media sentiment score of 1.50 beat BeOne Medicines' score of 0.02 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to RVMD or INSM?

In the previous week, Insmed had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 17 mentions for Insmed and 12 mentions for Revolution Medicines. Insmed's average media sentiment score of 1.50 beat Revolution Medicines' score of 0.60 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Insmed 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Insmed (INSM) Competitors

$103.73 -2.30 (-2.17%)

Closing price 06/2/2026 04:00 PM Eastern

Extended Trading

$102.62 -1.11 (-1.07%)

As of 07:06 AM Eastern

Compare

INSM vs. TAK, ARGX, TEVA, ONC, and RVMD

Should you buy Insmed stock or one of its competitors? MarketBeat compares Insmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insmed include Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does Insmed compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Takeda Pharmaceutical has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.71	$1.27B	$0.39	38.96
Insmed	$606.42M	37.08	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 15 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 17 mentions for Insmed and 2 mentions for Takeda Pharmaceutical. Insmed's average media sentiment score of 1.50 beat Takeda Pharmaceutical's score of 1.09 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Insmed has a consensus target price of $210.95, suggesting a potential upside of 103.37%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

9.2% of Takeda Pharmaceutical shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 4.31% compared to Insmed's net margin of -144.44%. Takeda Pharmaceutical's return on equity of 11.07% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Insmed	-144.44%	-130.11%	-51.57%

Summary

Insmed beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Insmed compare to argenex?

argenex (NASDAQ:ARGX) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.74	$1.29B	$22.46	35.72
Insmed	$606.42M	37.08	-$1.28B	-$5.75	N/A

argenex has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

argenex presently has a consensus price target of $1,019.50, suggesting a potential upside of 27.09%. Insmed has a consensus price target of $210.95, suggesting a potential upside of 103.37%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

argenex has a net margin of 31.31% compared to Insmed's net margin of -144.44%. argenex's return on equity of 33.28% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
Insmed	-144.44%	-130.11%	-51.57%

60.3% of argenex shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Insmed had 10 more articles in the media than argenex. MarketBeat recorded 17 mentions for Insmed and 7 mentions for argenex. Insmed's average media sentiment score of 1.50 beat argenex's score of 0.58 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

argenex beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Insmed compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, Teva Pharmaceutical Industries had 1 more articles in the media than Insmed. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 17 mentions for Insmed. Insmed's average media sentiment score of 1.50 beat Teva Pharmaceutical Industries' score of 1.37 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	13 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Teva Pharmaceutical Industries currently has a consensus target price of $41.78, indicating a potential upside of 26.68%. Insmed has a consensus target price of $210.95, indicating a potential upside of 103.37%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.20	$1.41B	$1.33	24.80
Insmed	$606.42M	37.08	-$1.28B	-$5.75	N/A

Teva Pharmaceutical Industries has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Insmed's net margin of -144.44%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
Insmed	-144.44%	-130.11%	-51.57%

Summary

Teva Pharmaceutical Industries beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Insmed compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Insmed had 5 more articles in the media than BeOne Medicines. MarketBeat recorded 17 mentions for Insmed and 12 mentions for BeOne Medicines. Insmed's average media sentiment score of 1.50 beat BeOne Medicines' score of 0.02 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

48.6% of BeOne Medicines shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

BeOne Medicines has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.64	$286.93M	$4.47	61.45
Insmed	$606.42M	37.08	-$1.28B	-$5.75	N/A

BeOne Medicines presently has a consensus price target of $390.00, indicating a potential upside of 41.98%. Insmed has a consensus price target of $210.95, indicating a potential upside of 103.37%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

BeOne Medicines has a net margin of 8.94% compared to Insmed's net margin of -144.44%. BeOne Medicines' return on equity of 12.06% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Insmed	-144.44%	-130.11%	-51.57%

Summary

BeOne Medicines beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Insmed compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Insmed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Revolution Medicines' return on equity of -83.22% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Insmed	-144.44%	-130.11%	-51.57%

Revolution Medicines currently has a consensus target price of $123.72, indicating a potential downside of 18.23%. Insmed has a consensus target price of $210.95, indicating a potential upside of 103.37%. Given Insmed's higher probable upside, analysts clearly believe Insmed is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

In the previous week, Insmed had 5 more articles in the media than Revolution Medicines. MarketBeat recorded 17 mentions for Insmed and 12 mentions for Revolution Medicines. Insmed's average media sentiment score of 1.50 beat Revolution Medicines' score of 0.60 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Insmed	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Revolution Medicines has higher earnings, but lower revenue than Insmed. Revolution Medicines is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,777.94	-$1.13B	-$7.07	N/A
Insmed	$606.42M	37.08	-$1.28B	-$5.75	N/A

94.3% of Revolution Medicines shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Revolution Medicines beats Insmed on 9 of the 17 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INSM vs. The Competition

Export

Metric	Insmed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.98B	$3.33B	$6.33B	$12.58B
Dividend Yield	N/A	2.34%	2.69%	5.45%
P/E Ratio	-18.04	17.44	21.02	24.51
Price / Sales	37.08	314.21	540.20	128.84
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	29.98	6.50	9.93	6.75
Net Income	-$1.28B	$24.15M	$3.56B	$337.19M
7 Day Performance	-2.51%	-2.46%	-0.44%	1.88%
1 Month Performance	-22.16%	1.16%	4.59%	6.59%
1 Year Performance	41.94%	46.65%	27.58%	35.52%

Insmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INSM Insmed	3.7815 of 5 stars	$103.73 -2.2%	$210.95 +103.4%	+44.7%	$22.98B	$606.42M	N/A	1,664	Positive News
TAK Takeda Pharmaceutical	3.6929 of 5 stars	$16.22 -0.2%	N/A	+0.8%	$51.71B	$28.32B	41.60	47,455	Positive News
ARGX argenex	4.209 of 5 stars	$806.46 flat	$1,017.78 +26.2%	+37.2%	$49.91B	$4.25B	35.91	1,863	Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.8966 of 5 stars	$34.04 -0.1%	$41.78 +22.7%	+91.1%	$39.17B	$17.26B	25.59	33,950
ONC BeOne Medicines	4.3984 of 5 stars	$310.25 flat	$389.15 +25.4%	+11.7%	$34.04B	$5.34B	69.41	12,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INSM) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Competitors

INSM vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Insmed compare to Takeda Pharmaceutical?

Summary

How does Insmed compare to argenex?

Summary

How does Insmed compare to Teva Pharmaceutical Industries?

Summary

How does Insmed compare to BeOne Medicines?

Summary

How does Insmed compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insmed (INSM) Competitors

INSM vs. TAK, ARGX, TEVA, ONC, and RVMD

How does Insmed compare to Takeda Pharmaceutical?

Which has more volatility & risk, TAK or INSM?

Which has preferable earnings and valuation, TAK or INSM?

Does the media refer more to TAK or INSM?

Do analysts recommend TAK or INSM?

Do insiders and institutionals hold more shares of TAK or INSM?

Is TAK or INSM more profitable?

Summary

How does Insmed compare to argenex?

Which has stronger valuation and earnings, ARGX or INSM?

Which has more risk and volatility, ARGX or INSM?

Do analysts recommend ARGX or INSM?

Is ARGX or INSM more profitable?

Do institutionals & insiders hold more shares of ARGX or INSM?

Does the media refer more to ARGX or INSM?

Summary

How does Insmed compare to Teva Pharmaceutical Industries?

Does the media refer more to TEVA or INSM?

Do analysts prefer TEVA or INSM?

Do insiders & institutionals believe in TEVA or INSM?

Which has stronger earnings & valuation, TEVA or INSM?

Which has more volatility & risk, TEVA or INSM?

Is TEVA or INSM more profitable?

Summary

How does Insmed compare to BeOne Medicines?

Does the media refer more to ONC or INSM?

Do insiders and institutionals believe in ONC or INSM?

Which has more risk and volatility, ONC or INSM?

Which has better valuation & earnings, ONC or INSM?

Do analysts rate ONC or INSM?

Is ONC or INSM more profitable?

Summary

How does Insmed compare to Revolution Medicines?

Which has more risk & volatility, RVMD or INSM?

Is RVMD or INSM more profitable?

Do analysts rate RVMD or INSM?

Does the media refer more to RVMD or INSM?

Which has higher earnings and valuation, RVMD or INSM?

Do insiders & institutionals believe in RVMD or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools